文献速递胸部肿瘤

肺腺癌血浆与肿瘤标本EGFR T790M突变检测一致性评价

[Evaluation of Consistency in detection of epidermal growth factor receptor gene T790M mutation in plasma and tumor specimens of patients with lung adenocarcinoma].
PubMed 文献 · Zhonghua Zhong Liu Za Zhi · 2018-01-01

该研究纳入12例可手术肺腺癌和100例进展期肺腺癌患者,配对比较血浆cSMART与肿瘤ARMS检测EGFR突变的一致性。进展期患者血浆与组织T790M的敏感度50.0%、特异度72.9%、一致率72.0%;健康志愿者血浆亦检出T790M突变。

要点

  • 进展期肺腺癌血浆与肿瘤T790M检测一致率仅72.0%。
  • L858R和19外显子缺失血浆检测一致率较高(98.0%、95.0%)。
  • 健康志愿者血浆中可检出低拷贝T790M突变(7/50)。

核心结论

  • 进展期肺腺癌患者血浆与肿瘤标本检测T790M突变的敏感度、特异度和一致率均较低。
  • 健康志愿者血浆中存在T790M突变,提示其可能参与EGFR信号通路调节并在健康人群中有一定生理功能。

研究设计与样本

  • 收集12例可手术切除(Ⅰ~ⅢA期)及100例进展期(ⅢB~Ⅳ期)肺腺癌患者的组织或细胞学肿瘤标本,其中11例为吉非替尼获得性耐药患者,并配对采集外周血。
  • 同期获得50例健康志愿者外周血标本。
  • 肿瘤标本采用扩增受阻突变系统(ARMS)检测EGFR基因突变,配对血浆标本采用二代测序环化单分子扩增和重测序技术(cSMART)检测循环肿瘤DNA EGFR基因突变。

主要发现

  • 100例进展期肺腺癌患者血浆与肿瘤标本中,T790M突变的敏感度、特异度和一致率分别为50.0%、72.9%和72.0%。
  • L858R突变的敏感度、特异度和一致率分别为91.7%、100.0%和98.0%,19外显子缺失突变分别为79.2%、100.0%和95.0%。
  • 50例健康志愿者血浆中T790M突变[(1.0±0.0)拷贝]7例(14.0%),未检出L858R突变和19外显子缺失突变。
  • 12例可手术切除肺腺癌患者血浆中T790M突变[(1.2±0.2)拷贝]4例(33.3%),未检出L858R和19外显子缺失突变。
  • 100例进展期肺腺癌患者血浆中T790M位点突变28例(28.0%),拷贝数为(34.0±22.7)拷贝;11例获得性吉非替尼耐药患者血浆中T790M突变5例,拷贝数为(268.2±119.9)拷贝。

临床怎么用

  • 血浆T790M检测与肿瘤标本一致性有限,临床解读需谨慎并结合组织检测。
  • 健康人群血浆可检出低拷贝T790M,需注意假阳性可能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To evaluate the consistency in detection of T790M mutation of epidermal growth factor receptor gene (EGFR) in plasma and tumor samples of patients with lung adenocarcinoma. Methods: The tumor tissues or cytological specimens of 12 patients with operable lung adenocarcinoma(stage Ⅰ-ⅢA) and 100 patients with advanced stage ⅢB-Ⅳ lung adenocarcinoma were collected, among which 11 patients showed acquired resistance for gefitinib (11/100). In the same period, peripheral blood samples were collected from all patients and 50 healthy volunteers. Amplification refractory mutation system (ARMS) was used to detect EGFR mutations in tumor specimens. Next Generation Sequencing(NGS) based circulating single-molecule amplification and resequencing technology (cSMART)was performed to quantitatively detect the EGFR mutations in circulating tumor DNA (ctDNA) from plasma specimens. Results: The sensitivity, specificity and concordance rate of EGFR T790M mutation between plasma and tissue specimens from 100 advanced stage patients were 50.0%, 72.9% and 72.0%, respectively. For L858R mutation and exon 19 deletion mutations, the above mentioned sensitivity, specificity and concordance rate were 91.7%, 100.0%, and 98.0%, as well as 79.2%, 100.0% and 95.0%, respectively. The L858R mutation and exon 19 deletion mutations were not detected in plasma of 50 healthy volunteers, whereasT790M mutation(1.0±0.0 copies) was found in 7 individuals(7/50, 14.0%). Similarly, in 12 resectable patients, 4 (4/12, 33.3%) T790M mutations were found in plasma (1.2±0.2 copies), but no L858R mutation and 19 exon deletion mutations. In comparison, 28.0% of patients with advanced lung adenocarcinoma (28/100)had detectable T790M mutation in plasma with copy numbers (34.0±22.7 copies). Furthermore, the copy numbers of T790M were 268.2±119.9 in plasma of 5 cases with acquired gefitinib-resistance. Conclusions: In patients with advanced stages of lung adenocarcinoma, the detection of T790M mutation in plasma and tumor specimens is low. The T790M mutation also exists in the plasma of some healthy controls, suggesting that T790M mutation participates in EGFR signaling pathway and it might function in healthy population. 目的: 探讨肺腺癌患者血浆和肿瘤标本中表皮生长因子受体(EGFR)基因T790M位点突变检测结果的一致性。 方法: 收集12例可手术切除(Ⅰ~ⅢA期)及100例进展期(ⅢB~Ⅳ期)肺腺癌患者的组织或细胞学肿瘤标本,其中11例标本为吉非替尼获得性耐药患者,并配对采集患者外周血标本。同期获得50例健康志愿者外周血标本。肿瘤标本采用扩增受阻突变系统方法检测EGFR基因突变,配对血浆标本采用二代测序环化单分子扩增和重测序技术检测循环肿瘤DNA EGFR基因突变。 结果: 100例进展期肺腺癌患者血浆和肿瘤标本中,EGFR基因T790M位点突变的敏感度、特异度和一致率分别为50.0%、72.9%和72.0%,L858R位点突变的敏感度、特异度和一致率分别为91.7%、100.0%和98.0%,19外显子缺失突变的敏感度、特异度和一致率分别为79.2%、100.0%和95.0%。50例健康志愿者血浆中T790M突变[(1.0±0.0)拷贝] 7例(14.0%),未检出L858R突变和19外显子缺失突变。12例可手术切除肺腺癌患者血浆中,T790M突变[(1.2±0.2)拷贝] 4例(33.3%),未检出L858R和19外显子缺失突变。100例进展期肺腺癌患者血浆中,T790M位点突变28例(28.0%),拷贝数为(34.0±22.7)拷贝。11例获得性吉非替尼耐药患者血浆中,T790M突变5例,拷贝数为(268.2±119.9)拷贝。 结论: 进展期肺腺癌患者血浆及肿瘤标本中,检测T790M位点的敏感度、特异度和一致率低。健康志愿者血浆中存在T790M突变,可能提示T790M位点突变为EGFR信号传导路径的调节者,且在健康人群中具有一定的生理功能。.

来源:Zhonghua Zhong Liu Za Zhi,查看原文。版权归原作者所有。

引用

  1. Du J, Wang Z, Yang L, et al. [Evaluation of Consistency in detection of epidermal growth factor receptor gene T790M mutation in plasma and tumor specimens of patients with lung adenocarcinoma]. Zhonghua Zhong Liu Za Zhi. 2018. PMID: 29365415. doi:10.3760/cma.j.issn.0253-3766.2018.01.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。